查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1791210

Biktarvy 市場報告：2031 年趨勢、預測與競爭分析

Biktarvy Market Report: Trends, Forecast and Competitive Analysis to 2031
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球Biktarvy市場前景光明，醫院和零售藥局市場都蘊藏著巨大的機會。預計2025年至2031年期間，全球Biktarvy市場的複合年成長率將達到2.7%。推動該市場發展的關鍵因素包括愛滋病毒/愛滋病盛行率的上升、認知度的提升和篩檢計畫的推進，以及對單一藥物療法的日益偏好。

  • Lucintel 預測，按類型學名藥在預測期內將出現高速成長。
  • 從應用程式來看，零售藥局預計將實現高速成長。
  • 按地區分類，預計北美將在預測期內實現最高成長。

一份全面的 150 多頁報告提供了寶貴的見解，為您的業務決策提供參考。

Biktarvy市場的新趨勢

Biktarvy 市場強勁，但並非一成不變。一些關鍵趨勢正在湧現，這些趨勢將決定其未來發展方向以及在整個 HIV 治療領域中的地位。這些趨勢包括：長效注射劑的研發和廣泛應用、對合併症患者治療的重視程度不斷提高、暴露前預防 (PrEP) 的推廣應用、單藥治療方案的持續重要性，以及專利到期和學名藥競爭的潛在影響。了解這些趨勢對於預測未來市場趨勢至關重要。

  • 長效注射療法：包括卡博特韋和利匹韋林（Cabenuva）在內的長效注射抗逆轉錄病毒療法的開發和使用日益增多，是愛滋病治療領域的一大趨勢。這些治療方法的優點在於給藥頻率較低（例如每月或每兩個月一次），從而可以最大限度地減少錠劑負擔，從而提高患者的依從性和滿意度。雖然比克托維（Biktarvy）是一種簡單的每日一次口服方案，但較低的給藥頻率可能對部分患者俱有吸引力，並可能長期影響比克托維的市場佔有率。
  • 更重視合併症患者的治療：HIV 感染者通常患有併發症，包括心血管疾病、腎功能受損和骨骼健康受損。因此，我們需要一種不僅能有效抑制病毒，而且安全且耐受性良好的 HIV 治療藥物，並考慮到這些合併症。目前正在進行的研究和臨床試驗正在探索 Biktarvy 對老年患者和合併症患者的長期數據，這凸顯了滿足這些複雜患者需求的重要性。
  • 暴露前預防的擴展：雖然Biktarvy本身尚未核准作為PrEP，但對HIV預防方案的日益關注以及PrEP使用的擴大將影響整個HIV市場的規模。 PrEP在預防HIV新興感染的有效性，反過來可能影響未來治療市場的規模。 Biktarvy的生產商吉利德公司憑藉Decoy等其他藥物在PrEP市場佔有一席之地，這表明該公司在治療和預防方面擁有更廣泛的戰略利益。新型長效PrEP的推出可能會進一步改變這個局面。
  • 錠劑療法的持續優勢：Biktarvy 等單片療法因其簡單易用且更易於堅持，已成為大多數 HIV 感染者的標準治療方法方案。每日只需服用一片，方便快捷，使治療更輕鬆，並帶來更佳療效。 Biktarvy 的成功源自於其小劑量但有效且安全性可耐受的單片療法 (STR)。這一趨勢意味著單片療法將保持顯著的市場佔有率，但它們將面臨來自更新、長效產品的競爭。
  • 專利到期和學名藥競爭的潛在影響：雖然Biktarvy目前受專利保護，但專利最終將到期，使其容易受到學名藥。學名藥抗逆轉錄病毒藥物有可能大幅降低治療成本，並衝擊Biktarvy等品牌藥的市場佔有率和收益。吉利德必須為未來的競爭做好準備，並開發新的創新HIV治療方案，以維持其市場主導地位。

所有這些新興趨勢正在共同重塑Biktarvy市場。儘管Biktarvy目前作為單藥療法佔據領先地位，但它必須適應長效注射劑日益普及以及對合併症患者治療日益成長的重視。 PrEP的成長可能會影響該療法的整體市場規模，而學名藥的上市最終將給公司帶來價格壓力。吉利德的創新和治療開發能力將是駕馭這些不斷變化的市場動態並保持其在HIV治療領域強勢地位的關鍵。

Biktarvy市場的最新趨勢

目前圍繞Biktarvy市場的動態旨在鞏固其作為一線HIV治療藥物的領導地位。這些動態包括：推出長期療效和安全性數據；研究其在包括合併感染者在內的各類患者群體中的應用；以及評估旨在提升患者便利性和改善治療效果的新劑型。所有這些舉措都旨在擴大Biktarvy的用途，並鞏固其在新興HIV治療領域的地位。

  • 長期療效和安全性數據：正在進行的臨床和真實世界研究正在提供關於Biktarvy療效和安全性的長期數據。在包括逆轉錄病毒和機會性感染疾病會議 (CROI) 在內的主要科學會議上，報告通常顯示，Biktarvy治療患者的多年結果顯示其具有持久的病毒抑制效果和良好的安全性，支持Biktarvy作為一種穩定的長期治療選擇。
  • 特定患者群體研究：目前正在進行研究，評估比克托丙酸 (Biktarvy) 在特定 HIV 感染者亞群中的有效性和安全性。這些研究涵蓋初治患者、從其他抗逆轉錄病毒病毒療法轉換的患者、老年人以及合併症患者（例如乙肝病毒 (HBV) 合併感染）。這些研究結果將有助於指南治療，並擴大對比克托丙酸對更廣泛患者群體的價值的認知。例如，已證實在 HIV/HBV 合併感染患者中，轉換至比克托丙酸後病毒抑制率較高。
  • 考慮新的配方和給藥方法：Biktarvy 目前為每日一次的口服錠劑；然而，HIV 治療領域正在積極研究長效配方。雖然短期內並非僅針對 Biktarvy，但藥物輸送系統的技術進步可能會導致未來對 Biktarvy 或其各個成分進行重新配方，以進一步提高便利性和依從性。
  • 與其他抗逆轉錄病毒療法相比的相對療效和安全性研究：為了進一步明確Biktarvy在治療領域的地位，我們正在臨床試驗中將其與其他廣泛使用的抗逆轉錄病毒療法進行比較。這些臨床試驗評估了Biktarvy的療效、安全性和耐受性，以幫助臨床醫生做出明智的治療決策。這些療效和安全性比較研究的正面結果支持將Biktarvy推薦為第一線治療方案。
  • 收集真實世界證據 在受控臨床試驗之外，收集和分析真實世界證據正變得越來越重要。這些研究透過確定Biktarvy在臨床試驗罕見方案條件之外的異質性患者群體中的療效和耐受性，來評估其在真實世界條件下的效果。真實世界證據可用於補充臨床試驗訊息，並進一步有助於制定治療建議。

這些最新進展凸顯了Biktarvy在HIV管理中最大化應用的持續努力。不斷累積的縱向數據、特殊人群研究以及HIV治療研究的總體趨勢，都有助於更好地理解Biktarvy在改善HIV感染者生活方面的地位和前景。這些進展進一步證明了Biktarvy在現代HIV治療時代的關鍵作用。

目錄

第1章執行摘要

第2章 市場概述

  • 背景和分類
  • 供應鏈

第3章：市場趨勢與預測分析

  • 宏觀經濟趨勢與預測
  • 產業驅動力與挑戰
  • PESTLE分析
  • 專利分析
  • 法規環境

第4章全球Biktarvy 市場（按類型）

  • 概述
  • 按類型進行吸引力分析
  • 原始藥物：趨勢與預測（2019-2031）
  • 學名藥：趨勢與預測（2019-2031）

第5章全球Biktarvy 市場（按應用）

  • 概述
  • 按用途進行吸引力分析
  • 醫院：趨勢與預測（2019-2031）
  • 零售藥局：趨勢與預測（2019-2031）
  • 其他：趨勢與預測（2019-2031）

第6章區域分析

  • 概述
  • 全球 Biktarvy 市場（按地區）

第7章 北美 Biktarvy 市場

  • 概述
  • 北美 Biktarvy 市場（按類型）
  • 北美 Biktarvy 市場（按應用）
  • Biktarvy 在美國的市場
  • 墨西哥的Biktarby市場
  • 加拿大 Biktarbi 市場

第8章 歐洲 Biktarvy 市場

  • 概述
  • 歐洲 Biktarvy 市場類型
  • 歐洲 Biktarvy 市場（按應用）
  • 德國 Biktarby 市場
  • 法國的Biktarbi市場
  • 西班牙的Biktarbi市場
  • 義大利 Biktarbi 市場
  • 英國Biktarvy 市場

第9章亞太地區 Biktarvy 市場

  • 概述
  • 亞太地區 Biktarvy 市場類型
  • 亞太地區 Biktarvy 市場（按應用）
  • 日本的Biktarvy市場
  • 印度的Biktarbi市場
  • 中國的Biktarvy市場
  • 韓國的Biktarbi市場
  • 印尼的Biktarbi市場

第10章 其他地區的 Biktarbi 市場

  • 概述
  • 其他地區 Biktarbi 市場（按類型）
  • 世界其他地區 Biktarbi 市場（按應用）
  • 中東的Biktarbi市場
  • 南美的 Biktarvy 市場
  • 非洲 Biktarbi 市場

第11章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析
    • 競爭對手之間的競爭
    • 買方的議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 新進入者的威脅
  • 市場佔有率分析

第12章機會與策略分析

  • 價值鏈分析
  • 成長機會分析
    • 按類型分類的成長機會
    • 按應用分類的成長機會
  • 全球 Biktarvy 市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 認證和許可
    • 合併、收購、協議、合作和合資企業

第13章：價值鏈主要企業的公司簡介

  • 競爭分析
  • Gilead Sciences
  • ABACUS MEDICINE
  • Hetero Drugs
  • Gador
  • BMODESTO

第14章 附錄

  • List of Figures
  • List of Tables
  • Research Methodology
  • Disclaimer
  • Copyright
  • Abbreviations and Technical Units
  • About Us
  • Contact Us

The future of the global Biktarvy market looks promising with opportunities in the hospital and retail pharmacy markets. The global Biktarvy market is expected to grow with a CAGR of 2.7% from 2025 to 2031. The major drivers for this market are the rising prevalence of HIV/AIDS, the growing awareness & screening programs, and the increasing preference for single-tablet regimens.

  • Lucintel forecasts that, within the type category, generic drugs are expected to witness higher growth over the forecast period.
  • Within the application category, retail pharmacy is expected to witness higher growth.
  • In terms of region, North America is expected to witness the highest growth over the forecast period.

Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.

Emerging Trends in the Biktarvy Market

The Biktarvy market, as strong as it is, is not fixed. A number of very important trends are emerging that will shape its future direction and position within the overall HIV treatment environment. Some of these trends involve the creation and uptake of long-acting injectable treatments, the growing emphasis on the treatment of patients with comorbidities, the growing use of pre-exposure prophylaxis (PrEP), the continued relevance of single-tablet regimens, and the possible influence of patent losses and generic competition. Knowledge of these trends is essential to forecast future market trends.

  • Long-Acting Injectable Therapies: Development and increasing use of long-acting injectable antiretroviral therapies, including cabotegravir and rilpivirine (Cabenuva), are a major trend in HIV therapy. These treatments bring the benefit of less frequent dosing (e.g., monthly or bi-monthly), which can simplify patient adherence and patient satisfaction by minimizing the pill burden. Whereas Biktarvy is a simple once-daily oral regimen, the attractiveness of even less-frequent dosing will appeal to some patients and could affect Biktarvy's market share over the long term.
  • Increased Emphasis on Treating Patients with Comorbidities: Individuals with HIV are increasingly having comorbidities like cardiovascular disease, renal impairment, and bone health disorders. This requires HIV therapies that are not only efficacious in viral suppression but also safe and well-tolerated in the context of these other comorbidities. Long-term data on Biktarvy among older patients and those with comorbidities are being studied in ongoing research and clinical trials, which underscores the relevance of meeting these complicated patient requirements in the market.
  • Pre-Exposure Prophylaxis Expansion: Although Biktarvy itself is not approved for PrEP, the increasing focus on HIV prevention regimens and the growth in PrEP use impact the size of the overall HIV market. The effectiveness of PrEP in preventing new HIV infections can, in turn, affect the size of the treatment market in the future. Gilead, the company that makes Biktarvy, also has a presence in the market for PrEP with other medications such as Decoy, suggesting a more general strategic interest in both treatment and prevention. The introduction of new, long-acting PrEP forms may further shift the scene.
  • Ongoing Supremacy of Single-Tablet Regimens: Single-tablet regimens such as Biktarvy have become the standard of care for most individuals with HIV because they are simple and encourage improved adherence. The ease of taking only a single pill a day makes the treatment easier and can result in better outcomes. Biktarvy's success derives in part from its position as a small but effective STR that has a well-tolerated safety profile. This trend lines up with that STRs will maintain a very large share of the market though they will get competition from some new long-acting products on the horizon.
  • Potential Effect of Patent Expirations and Generic Competition: Although Biktarvy is now under patent protection, the eventual lapse of these patents will allow generic competition. Generic forms of antiretroviral drugs can dramatically reduce the cost of treatment, potentially affecting the market share and revenue of branded medications such as Biktarvy. Gilead must be planning for this future competition by creating new and innovative HIV treatments in order to preserve its market dominance.

These new trends are all combined to reshape the Biktarvy market. Although Biktarvy's current status as a top single-tablet regimen is robust, it will have to adjust to the growing availability of long-acting injectables and the expanding emphasis on treating patients with comorbidities. The growth of PrEP may impact the total treatment market size, and the eventual launch of generics will bring pricing pressures. Gilead's innovative capacity and therapeutic development capabilities will be key in navigating these shifting market dynamics and keeping a solid footing in the HIV treatment space.

Recent Developments in the Biktarvy Market

Current events surrounding the Biktarvy market are focused on affirming its leadership as a first-line HIV treatment. These events include the introduction of long-term efficacy and safety data, studies of its application in varied patient populations such as those with co-infections, and evaluation of new formulations to improve patient convenience and outcomes. All these are aimed at expanding Biktarvy's use and affirming its place in the emerging HIV treatment landscape.

  • Long-Term Efficacy and Safety Data: Ongoing clinical trials and real-world studies continue to generate long-term data on the efficacy and safety of Biktarvy. Presentations at key conferences, including the Conference on Retroviruses and Opportunistic Infections (CROI), typically include multi-year outcomes showing durable viral suppression and a good safety profile in patients receiving Biktarvy. This supports confidence in Biktarvy as a stable long-term treatment option.
  • Studies in Specific Patient Populations: Research is being conducted to evaluate the effectiveness and safety of Biktarvy in specific subgroups of people living with HIV. This includes studies in treatment-naive individuals, those switching from other antiretroviral regimens, older adults, and individuals with comorbidities such as hepatitis B virus (HBV) co-infection. Findings from these studies assist in guiding treatment and broadening the knowledge of Biktarvy's value to a wider group of patients. For instance, high viral suppression rates have been demonstrated in patients with HIV/HBV co-infection switching to Biktarvy.
  • Investigation of New Formulations and Delivery Options: Although Biktarvy is presently marketed as a once-daily oral tablet, there is active research across the overall HIV therapy space for long-acting formulations. Although nonspecific to Biktarvy in the short run, technology advances in drug delivery systems could in the future create reformulated versions of Biktarvy or its individual elements with the goal of further enhancing convenience and adherence.
  • Relative Efficacy and Safety Studies Compared to Other Antiretroviral Regimens: Further to define its position in therapy, Biktarvy has been compared to other widely used regimens of antiretroviral therapy through clinical trials. Relative efficacy, safety, and tolerability are all evaluated in such studies, which serve to help clinicians make informed treatment decisions. Favorable results from these relative efficacy and safety studies endorse Biktarvy as a preferred first-line treatment.
  • Collection of Real-World Evidence: Outside of controlled clinical trials, collection and analysis of real-world evidence are becoming more critical. These trials assess how Biktarvy works under real-world clinical practice conditions, revealing its efficacy and tolerability in a heterogeneous group of patients outside the rare protocol conditions of clinical trials. Real-world evidence can be used to supplement clinical trial information and contribute further to treatment recommendations.

These recent advances collectively emphasize the continued efforts to maximize the utilization of Biktarvy in HIV management. The accumulation of long-term data, research in special populations, and the general trends in HIV treatment research are all leading to a better understanding of Biktarvy's place and promise in enhancing the lives of individuals living with HIV. These advances serve to further establish Biktarvy as an integral part of the contemporary HIV treatment era.

Strategic Growth Opportunities in the Biktarvy Market

Strategic growth areas for Biktarvy are to build on its proven efficacy and safety profile to expand its use across various stages of HIV treatment. These areas are to consolidate its role in first-line treatment, emerge as the first choice among those switching treatment regimens, increase its use in patients with co-infections, and look into new formulations to make it more convenient for patients and improve adherence. Building on these areas can further enhance Biktarvy's market presence.

  • Initial Therapy for Naive Patients: Biktarvy has already made a significant name for itself as an initial therapy for newly diagnosed HIV individuals. Its ability to provide fast and sustained viral suppression, combined with its tolerability profile and single-tablet once-daily regimen, makes it an appealing choice for initial therapy. Ongoing efforts towards educating healthcare professionals and newly diagnosed patients about these advantages can further establish its place in this critical use.
  • Switch Therapy for Virologically Suppressed Patients: For patients who are already virologically suppressed on alternative antiretroviral regimens but perhaps having issues with tolerability, drug interactions, or pill burden, Biktarvy represents a streamlined and frequently better-tolerated option. Emphasizing Biktarvy as an exemplary switching option through clinical evidence illustrating superior outcomes or patient satisfaction can increase growth in this category.
  • HIV/HBV Co-infected Individuals Treatment: HIV patients usually present with co-infections, and one such common co-infection is hepatitis B. Biktarvy's efficacy in suppressing both HIV and HBV has been shown in studies, which makes it an important choice for this particular patient group. Increased research and education among healthcare providers who treat co-infected patients can increase Biktarvy's application in this important use.
  • Long-Acting Formulations Development: Although Biktarvy is already an oral tablet, the direction of long-acting injectable HIV treatments represents a future growth possibility. Gilead's knowledge in developing HIV drugs could be used to develop long-acting versions of Biktarvy or its active ingredients, providing improved convenience and adherence for those who want to take less medication more infrequently.
  • Pediatric and Adolescent Use: Another opportunity for growth is extending the approved indication of Biktarvy to younger age groups, such as pediatric and adolescent patients. Clinical trials assessing the safety and efficacy of Biktarvy in these patient groups, with subsequent regulatory approvals, can extend its use and offer effective treatment to children and adolescents with HIV.

These strategic growth prospects, from establishing its place in first-line treatment to investigating new forms and broadening its application in certain patient populations, have the potential to greatly affect the Biktarvy market. By targeting these, Gilead is able to further build on the asset strengths of Biktarvy to meet the changing needs of individuals living with HIV while solidifying its leadership in the antiretroviral category.

Biktarvy Market Driver and Challenges

The trajectory of the Biktarvy market is defined by an intersection of drivers and challenges that result from technological advances in HIV therapy, economic determinants affecting drug pricing and availability, and the changing regulatory environment that defines pharmaceutical approvals and guidelines. These dynamics are essential for stakeholders to effectively navigate the market and for individuals living with HIV to obtain best-in-class care.

The factors responsible for driving the Biktarvy market include:

1. High Efficacy and Tolerability: Biktarvy's proven high viral suppression rates and good safety profile are key drivers of its commercial success. Clinical trial and real-world evidence all demonstrate its ability to suppress HIV with fewer side effects, and so it is a first choice for both treatment-naive patients and treatment-experienced patients. Its robust clinical profile favors its prescription by clinicians.

2. Convenient Once-Daily Single-Tablet Regimen: The ease of once-daily single-tablet therapy greatly enhances treatment adherence. For those with a chronic illness such as HIV, pill burden reduction makes their daily life easier and more likely to maintain regular medication, resulting in improved virologic response. This ease is one of the key reasons Biktarvy is so well received.

3. Strong Recommendation in Treatment Guidelines: Most HIV treatment guidelines globally recommend INSTI-based regimens, such as Biktarvy, as the first-line therapy of choice. These recommendations, supported by strong clinical evidence, lead to the use of Biktarvy by healthcare providers as a safe and effective first-line treatment for the majority of individuals with HIV.

4. Ongoing Innovation in HIV Treatment: Ongoing research and development in the HIV sector lend support to success stories of medications such as Biktarvy. Ongoing developments in antiretroviral drugs, aiming for increased efficacy, lower toxicity, and easier convenience, push the market toward newer and superior treatment alternatives. Biktarvy is one such development, aided by the advances in INSTI development.

5. Increased Awareness and Access to HIV Treatment: Global efforts to increase awareness of HIV, increase testing, and enhance access to treatment drive the expansion of the overall HIV drug market, including Biktarvy. As more individuals become diagnosed and connected to care, demand for effective antiretroviral therapies such as Biktarvy continues to increase.

Challenges in the Biktarvy market are:

1. Competition from Other Antiretroviral Therapies: The market for HIV treatment is competitive, with a number of other effective antiretroviral regimens, including other single-tablet regimens and new long-acting injectable therapies. This competition can restrict Biktarvy's market share and impose pricing pressures as manufacturers compete for patient preference and payer coverage.

2. Pricing and Reimbursement Concerns: The affordability of newer antiretroviral agents such as Biktarvy may be problematic, especially where there are constraints in resources or limited insurance cover. Favorable pricing and proper reimbursement policies that are strong must be negotiated so that market access is sustained and widespread use of Biktarvy is enabled.

3. Risk for Long-Term Side Effects and Resistance: Though Biktarvy has a benign safety profile, the risk of long-term side effects, including some that will not be easily recognized, cannot be eliminated. Moreover, despite the high resistance barrier of Biktarvy, drug resistance, which can evolve over time, is a possibility with any antiretroviral regimen, possibly curtailing its long-term efficacy in certain patients.

The Biktarvy market is fueled by its high efficacy, tolerability, convenient presentation, and favorable positioning in treatment guidelines, within a backdrop of continuous innovation and expanding access to HIV care. But it has challenges posed by competition, price and reimbursement complexities, and long-term side effects or resistance risks. Managing these drivers and challenges will be essential for Biktarvy in order to preserve its market leadership and remain an essential part of HIV treatment.

List of Biktarvy Companies

  • Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies, Biktarvy companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the Biktarvy companies profiled in this report include:
  • Gilead Sciences
  • ABACUS MEDICINE
  • Hetero Drugs
  • Gador
  • BMODESTO

Biktarvy Market by Segment

The study includes a forecast for the global Biktarvy market by type, application, and region.

Biktarvy Market by Type [Value from 2019 to 2031]:

  • Brand Drugs
  • Generic Drugs

Biktarvy Market by Application [Value from 2019 to 2031]:

  • Hospitals
  • Retail Pharmacy
  • Others

Biktarvy Market by Region [Value from 2019 to 2031]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Biktarvy Market

The Biktarvy market, a major HIV treatment segment worldwide, keeps growing in major geographies. Trends are influenced by drivers like growing adoption rates, competition from established and emerging antiretroviral therapies, pricing trends, and regulatory regimes. Gilead Sciences' Biktarvy, a once-daily, single-tablet regimen, has become a popular treatment because of its efficacy, safety profile, and convenience. Yet, market conditions differ significantly between countries, shaped by local healthcare systems, economic conditions, and HIV prevalence. It is important for stakeholders in the pharmaceutical sector and people living with HIV to understand these regional differences.

  • United States: Biktarvy enjoys robust market leadership in the US, fueled by strong demand and favorable reimbursement. Sales continue to increase, with a 7% year-on-year increase seen in the first quarter of 2025, contributing largely to Gilead's overall revenues. Although long-acting injectables such as Cabenuva represent competitive pressure, Biktarvy's established track record of efficacy and the convenience of a once-daily oral regimen guarantee its continued solid standing. Recent price revisions have taken place, demonstrating a balance between revenue generation and market access for Gilead.
  • China: Data on recent developments specifically for Biktarvy in China are sparse in the available search results. The overall Chinese pharmaceutical market, though, is seeing growth in traditional and specialty pharmaceuticals. Single-tablet regimens are becoming the norm for HIV, with branded therapies such as Biktarvy gaining strong share in the HIV segment. The overall pharmaceutical trend suggests a growing market for innovative treatments, which could positively impact Biktarvy's future trajectory in the region.
  • Germany: There are no specific recent developments on Biktarvy in Germany set out in the search results given. Nevertheless, Germany is a major market across Europe, and trends in other large European markets, including attention to single-tablet regimens and the effect of pricing and reimbursement policy, are likely applicable. The general European market will experience competitive prices as a result of policy action, which might influence the market dynamics of Biktarvy in Germany.
  • India: The search results do not yield particular recent updates on Biktarvy in India. The Indian pharma industry is, however, interested in bolstering its infrastructure to be a world leader. The overall antiviral drug market is growing, led by the rise in viral disease prevalence. As much as Biktarvy is an important global product, its particular market trends in India would be determined by local prices, access initiatives, and the availability of generic antiretrovirals.
  • Japan: Recent data suggest that Biktarvy is approved and on the market in Japan. This evidence has been presented at international meetings by Gilead, highlighting the safety and efficacy of Biktarvy across a range of patient subgroups. Japan, as with other developed countries, would prefer effective, convenient HIV treatment, which would play in the favor of Biktarvy. Market conditions would be shaped by the healthcare system and regulation in Japan.

Features of the Global Biktarvy Market

  • Market Size Estimates: Biktarvy market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
  • Segmentation Analysis: Biktarvy market size by type, application, and region in terms of value ($B).
  • Regional Analysis: Biktarvy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the Biktarvy market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the Biktarvy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers the following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the Biktarvy market by type (brand drugs and generic drugs), application (hospitals, retail pharmacy, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.1 Macroeconomic Trends and Forecasts
  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Biktarvy Market by Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Type
  • 4.3 Brand Drugs: Trends and Forecast (2019-2031)
  • 4.4 Generic Drugs: Trends and Forecast (2019-2031)

5. Global Biktarvy Market by Application

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Application
  • 5.3 Hospitals: Trends and Forecast (2019-2031)
  • 5.4 Retail Pharmacy: Trends and Forecast (2019-2031)
  • 5.5 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

  • 6.1 Overview
  • 6.2 Global Biktarvy Market by Region

7. North American Biktarvy Market

  • 7.1 Overview
  • 7.2 North American Biktarvy Market by Type
  • 7.3 North American Biktarvy Market by Application
  • 7.4 United States Biktarvy Market
  • 7.5 Mexican Biktarvy Market
  • 7.6 Canadian Biktarvy Market

8. European Biktarvy Market

  • 8.1 Overview
  • 8.2 European Biktarvy Market by Type
  • 8.3 European Biktarvy Market by Application
  • 8.4 German Biktarvy Market
  • 8.5 French Biktarvy Market
  • 8.6 Spanish Biktarvy Market
  • 8.7 Italian Biktarvy Market
  • 8.8 United Kingdom Biktarvy Market

9. APAC Biktarvy Market

  • 9.1 Overview
  • 9.2 APAC Biktarvy Market by Type
  • 9.3 APAC Biktarvy Market by Application
  • 9.4 Japanese Biktarvy Market
  • 9.5 Indian Biktarvy Market
  • 9.6 Chinese Biktarvy Market
  • 9.7 South Korean Biktarvy Market
  • 9.8 Indonesian Biktarvy Market

10. ROW Biktarvy Market

  • 10.1 Overview
  • 10.2 ROW Biktarvy Market by Type
  • 10.3 ROW Biktarvy Market by Application
  • 10.4 Middle Eastern Biktarvy Market
  • 10.5 South American Biktarvy Market
  • 10.6 African Biktarvy Market

11. Competitor Analysis

  • 11.1 Product Portfolio Analysis
  • 11.2 Operational Integration
  • 11.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Growth Opportunity Analysis
    • 12.2.1 Growth Opportunities by Type
    • 12.2.2 Growth Opportunities by Application
  • 12.3 Emerging Trends in the Global Biktarvy Market
  • 12.4 Strategic Analysis
    • 12.4.1 New Product Development
    • 12.4.2 Certification and Licensing
    • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

  • 13.1 Competitive Analysis
  • 13.2 Gilead Sciences
    • Company Overview
    • Biktarvy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.3 ABACUS MEDICINE
    • Company Overview
    • Biktarvy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.4 Hetero Drugs
    • Company Overview
    • Biktarvy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.5 Gador
    • Company Overview
    • Biktarvy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.6 BMODESTO
    • Company Overview
    • Biktarvy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

14. Appendix

  • 14.1 List of Figures
  • 14.2 List of Tables
  • 14.3 Research Methodology
  • 14.4 Disclaimer
  • 14.5 Copyright
  • 14.6 Abbreviations and Technical Units
  • 14.7 About Us
  • 14.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global Biktarvy Market
  • Figure 2.1: Usage of Biktarvy Market
  • Figure 2.2: Classification of the Global Biktarvy Market
  • Figure 2.3: Supply Chain of the Global Biktarvy Market
  • Figure 2.4: Driver and Challenges of the Biktarvy Market
  • Figure 3.1: Trends of the Global GDP Growth Rate
  • Figure 3.2: Trends of the Global Population Growth Rate
  • Figure 3.3: Trends of the Global Inflation Rate
  • Figure 3.4: Trends of the Global Unemployment Rate
  • Figure 3.5: Trends of the Regional GDP Growth Rate
  • Figure 3.6: Trends of the Regional Population Growth Rate
  • Figure 3.7: Trends of the Regional Inflation Rate
  • Figure 3.8: Trends of the Regional Unemployment Rate
  • Figure 3.9: Trends of Regional Per Capita Income
  • Figure 3.10: Forecast for the Global GDP Growth Rate
  • Figure 3.11: Forecast for the Global Population Growth Rate
  • Figure 3.12: Forecast for the Global Inflation Rate
  • Figure 3.13: Forecast for the Global Unemployment Rate
  • Figure 3.14: Forecast for the Regional GDP Growth Rate
  • Figure 3.15: Forecast for the Regional Population Growth Rate
  • Figure 3.16: Forecast for the Regional Inflation Rate
  • Figure 3.17: Forecast for the Regional Unemployment Rate
  • Figure 3.18: Forecast for Regional Per Capita Income
  • Figure 4.1: Global Biktarvy Market by Type in 2019, 2024, and 2031
  • Figure 4.2: Trends of the Global Biktarvy Market ($B) by Type
  • Figure 4.3: Forecast for the Global Biktarvy Market ($B) by Type
  • Figure 4.4: Trends and Forecast for Brand Drugs in the Global Biktarvy Market (2019-2031)
  • Figure 4.5: Trends and Forecast for Generic Drugs in the Global Biktarvy Market (2019-2031)
  • Figure 5.1: Global Biktarvy Market by Application in 2019, 2024, and 2031
  • Figure 5.2: Trends of the Global Biktarvy Market ($B) by Application
  • Figure 5.3: Forecast for the Global Biktarvy Market ($B) by Application
  • Figure 5.4: Trends and Forecast for Hospitals in the Global Biktarvy Market (2019-2031)
  • Figure 5.5: Trends and Forecast for Retail Pharmacy in the Global Biktarvy Market (2019-2031)
  • Figure 5.6: Trends and Forecast for Others in the Global Biktarvy Market (2019-2031)
  • Figure 6.1: Trends of the Global Biktarvy Market ($B) by Region (2019-2024)
  • Figure 6.2: Forecast for the Global Biktarvy Market ($B) by Region (2025-2031)
  • Figure 7.1: Trends and Forecast for the North American Biktarvy Market (2019-2031)
  • Figure 7.2: North American Biktarvy Market by Type in 2019, 2024, and 2031
  • Figure 7.3: Trends of the North American Biktarvy Market ($B) by Type (2019-2024)
  • Figure 7.4: Forecast for the North American Biktarvy Market ($B) by Type (2025-2031)
  • Figure 7.5: North American Biktarvy Market by Application in 2019, 2024, and 2031
  • Figure 7.6: Trends of the North American Biktarvy Market ($B) by Application (2019-2024)
  • Figure 7.7: Forecast for the North American Biktarvy Market ($B) by Application (2025-2031)
  • Figure 7.8: Trends and Forecast for the United States Biktarvy Market ($B) (2019-2031)
  • Figure 7.9: Trends and Forecast for the Mexican Biktarvy Market ($B) (2019-2031)
  • Figure 7.10: Trends and Forecast for the Canadian Biktarvy Market ($B) (2019-2031)
  • Figure 8.1: Trends and Forecast for the European Biktarvy Market (2019-2031)
  • Figure 8.2: European Biktarvy Market by Type in 2019, 2024, and 2031
  • Figure 8.3: Trends of the European Biktarvy Market ($B) by Type (2019-2024)
  • Figure 8.4: Forecast for the European Biktarvy Market ($B) by Type (2025-2031)
  • Figure 8.5: European Biktarvy Market by Application in 2019, 2024, and 2031
  • Figure 8.6: Trends of the European Biktarvy Market ($B) by Application (2019-2024)
  • Figure 8.7: Forecast for the European Biktarvy Market ($B) by Application (2025-2031)
  • Figure 8.8: Trends and Forecast for the German Biktarvy Market ($B) (2019-2031)
  • Figure 8.9: Trends and Forecast for the French Biktarvy Market ($B) (2019-2031)
  • Figure 8.10: Trends and Forecast for the Spanish Biktarvy Market ($B) (2019-2031)
  • Figure 8.11: Trends and Forecast for the Italian Biktarvy Market ($B) (2019-2031)
  • Figure 8.12: Trends and Forecast for the United Kingdom Biktarvy Market ($B) (2019-2031)
  • Figure 9.1: Trends and Forecast for the APAC Biktarvy Market (2019-2031)
  • Figure 9.2: APAC Biktarvy Market by Type in 2019, 2024, and 2031
  • Figure 9.3: Trends of the APAC Biktarvy Market ($B) by Type (2019-2024)
  • Figure 9.4: Forecast for the APAC Biktarvy Market ($B) by Type (2025-2031)
  • Figure 9.5: APAC Biktarvy Market by Application in 2019, 2024, and 2031
  • Figure 9.6: Trends of the APAC Biktarvy Market ($B) by Application (2019-2024)
  • Figure 9.7: Forecast for the APAC Biktarvy Market ($B) by Application (2025-2031)
  • Figure 9.8: Trends and Forecast for the Japanese Biktarvy Market ($B) (2019-2031)
  • Figure 9.9: Trends and Forecast for the Indian Biktarvy Market ($B) (2019-2031)
  • Figure 9.10: Trends and Forecast for the Chinese Biktarvy Market ($B) (2019-2031)
  • Figure 9.11: Trends and Forecast for the South Korean Biktarvy Market ($B) (2019-2031)
  • Figure 9.12: Trends and Forecast for the Indonesian Biktarvy Market ($B) (2019-2031)
  • Figure 10.1: Trends and Forecast for the ROW Biktarvy Market (2019-2031)
  • Figure 10.2: ROW Biktarvy Market by Type in 2019, 2024, and 2031
  • Figure 10.3: Trends of the ROW Biktarvy Market ($B) by Type (2019-2024)
  • Figure 10.4: Forecast for the ROW Biktarvy Market ($B) by Type (2025-2031)
  • Figure 10.5: ROW Biktarvy Market by Application in 2019, 2024, and 2031
  • Figure 10.6: Trends of the ROW Biktarvy Market ($B) by Application (2019-2024)
  • Figure 10.7: Forecast for the ROW Biktarvy Market ($B) by Application (2025-2031)
  • Figure 10.8: Trends and Forecast for the Middle Eastern Biktarvy Market ($B) (2019-2031)
  • Figure 10.9: Trends and Forecast for the South American Biktarvy Market ($B) (2019-2031)
  • Figure 10.10: Trends and Forecast for the African Biktarvy Market ($B) (2019-2031)
  • Figure 11.1: Porter's Five Forces Analysis of the Global Biktarvy Market
  • Figure 11.2: Market Share (%) of Top Players in the Global Biktarvy Market (2024)
  • Figure 12.1: Growth Opportunities for the Global Biktarvy Market by Type
  • Figure 12.2: Growth Opportunities for the Global Biktarvy Market by Application
  • Figure 12.3: Growth Opportunities for the Global Biktarvy Market by Region
  • Figure 12.4: Emerging Trends in the Global Biktarvy Market

List of Tables

  • Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Biktarvy Market by Type and Application
  • Table 1.2: Attractiveness Analysis for the Biktarvy Market by Region
  • Table 1.3: Global Biktarvy Market Parameters and Attributes
  • Table 3.1: Trends of the Global Biktarvy Market (2019-2024)
  • Table 3.2: Forecast for the Global Biktarvy Market (2025-2031)
  • Table 4.1: Attractiveness Analysis for the Global Biktarvy Market by Type
  • Table 4.2: Market Size and CAGR of Various Type in the Global Biktarvy Market (2019-2024)
  • Table 4.3: Market Size and CAGR of Various Type in the Global Biktarvy Market (2025-2031)
  • Table 4.4: Trends of Brand Drugs in the Global Biktarvy Market (2019-2024)
  • Table 4.5: Forecast for Brand Drugs in the Global Biktarvy Market (2025-2031)
  • Table 4.6: Trends of Generic Drugs in the Global Biktarvy Market (2019-2024)
  • Table 4.7: Forecast for Generic Drugs in the Global Biktarvy Market (2025-2031)
  • Table 5.1: Attractiveness Analysis for the Global Biktarvy Market by Application
  • Table 5.2: Market Size and CAGR of Various Application in the Global Biktarvy Market (2019-2024)
  • Table 5.3: Market Size and CAGR of Various Application in the Global Biktarvy Market (2025-2031)
  • Table 5.4: Trends of Hospitals in the Global Biktarvy Market (2019-2024)
  • Table 5.5: Forecast for Hospitals in the Global Biktarvy Market (2025-2031)
  • Table 5.6: Trends of Retail Pharmacy in the Global Biktarvy Market (2019-2024)
  • Table 5.7: Forecast for Retail Pharmacy in the Global Biktarvy Market (2025-2031)
  • Table 5.8: Trends of Others in the Global Biktarvy Market (2019-2024)
  • Table 5.9: Forecast for Others in the Global Biktarvy Market (2025-2031)
  • Table 6.1: Market Size and CAGR of Various Regions in the Global Biktarvy Market (2019-2024)
  • Table 6.2: Market Size and CAGR of Various Regions in the Global Biktarvy Market (2025-2031)
  • Table 7.1: Trends of the North American Biktarvy Market (2019-2024)
  • Table 7.2: Forecast for the North American Biktarvy Market (2025-2031)
  • Table 7.3: Market Size and CAGR of Various Type in the North American Biktarvy Market (2019-2024)
  • Table 7.4: Market Size and CAGR of Various Type in the North American Biktarvy Market (2025-2031)
  • Table 7.5: Market Size and CAGR of Various Application in the North American Biktarvy Market (2019-2024)
  • Table 7.6: Market Size and CAGR of Various Application in the North American Biktarvy Market (2025-2031)
  • Table 7.7: Trends and Forecast for the United States Biktarvy Market (2019-2031)
  • Table 7.8: Trends and Forecast for the Mexican Biktarvy Market (2019-2031)
  • Table 7.9: Trends and Forecast for the Canadian Biktarvy Market (2019-2031)
  • Table 8.1: Trends of the European Biktarvy Market (2019-2024)
  • Table 8.2: Forecast for the European Biktarvy Market (2025-2031)
  • Table 8.3: Market Size and CAGR of Various Type in the European Biktarvy Market (2019-2024)
  • Table 8.4: Market Size and CAGR of Various Type in the European Biktarvy Market (2025-2031)
  • Table 8.5: Market Size and CAGR of Various Application in the European Biktarvy Market (2019-2024)
  • Table 8.6: Market Size and CAGR of Various Application in the European Biktarvy Market (2025-2031)
  • Table 8.7: Trends and Forecast for the German Biktarvy Market (2019-2031)
  • Table 8.8: Trends and Forecast for the French Biktarvy Market (2019-2031)
  • Table 8.9: Trends and Forecast for the Spanish Biktarvy Market (2019-2031)
  • Table 8.10: Trends and Forecast for the Italian Biktarvy Market (2019-2031)
  • Table 8.11: Trends and Forecast for the United Kingdom Biktarvy Market (2019-2031)
  • Table 9.1: Trends of the APAC Biktarvy Market (2019-2024)
  • Table 9.2: Forecast for the APAC Biktarvy Market (2025-2031)
  • Table 9.3: Market Size and CAGR of Various Type in the APAC Biktarvy Market (2019-2024)
  • Table 9.4: Market Size and CAGR of Various Type in the APAC Biktarvy Market (2025-2031)
  • Table 9.5: Market Size and CAGR of Various Application in the APAC Biktarvy Market (2019-2024)
  • Table 9.6: Market Size and CAGR of Various Application in the APAC Biktarvy Market (2025-2031)
  • Table 9.7: Trends and Forecast for the Japanese Biktarvy Market (2019-2031)
  • Table 9.8: Trends and Forecast for the Indian Biktarvy Market (2019-2031)
  • Table 9.9: Trends and Forecast for the Chinese Biktarvy Market (2019-2031)
  • Table 9.10: Trends and Forecast for the South Korean Biktarvy Market (2019-2031)
  • Table 9.11: Trends and Forecast for the Indonesian Biktarvy Market (2019-2031)
  • Table 10.1: Trends of the ROW Biktarvy Market (2019-2024)
  • Table 10.2: Forecast for the ROW Biktarvy Market (2025-2031)
  • Table 10.3: Market Size and CAGR of Various Type in the ROW Biktarvy Market (2019-2024)
  • Table 10.4: Market Size and CAGR of Various Type in the ROW Biktarvy Market (2025-2031)
  • Table 10.5: Market Size and CAGR of Various Application in the ROW Biktarvy Market (2019-2024)
  • Table 10.6: Market Size and CAGR of Various Application in the ROW Biktarvy Market (2025-2031)
  • Table 10.7: Trends and Forecast for the Middle Eastern Biktarvy Market (2019-2031)
  • Table 10.8: Trends and Forecast for the South American Biktarvy Market (2019-2031)
  • Table 10.9: Trends and Forecast for the African Biktarvy Market (2019-2031)
  • Table 11.1: Product Mapping of Biktarvy Suppliers Based on Segments
  • Table 11.2: Operational Integration of Biktarvy Manufacturers
  • Table 11.3: Rankings of Suppliers Based on Biktarvy Revenue
  • Table 12.1: New Product Launches by Major Biktarvy Producers (2019-2024)
  • Table 12.2: Certification Acquired by Major Competitor in the Global Biktarvy Market